DK3681864T3 - MODULATORS OF THE CYSTIC FIBROSE TRANSMEMBRANE CONDUCTIVE POWER REGULATOR PROTEIN AND METHODS OF USE - Google Patents

MODULATORS OF THE CYSTIC FIBROSE TRANSMEMBRANE CONDUCTIVE POWER REGULATOR PROTEIN AND METHODS OF USE Download PDF

Info

Publication number
DK3681864T3
DK3681864T3 DK18779798.0T DK18779798T DK3681864T3 DK 3681864 T3 DK3681864 T3 DK 3681864T3 DK 18779798 T DK18779798 T DK 18779798T DK 3681864 T3 DK3681864 T3 DK 3681864T3
Authority
DK
Denmark
Prior art keywords
fibrose
cystic
modulators
methods
power regulator
Prior art date
Application number
DK18779798.0T
Other languages
Danish (da)
Inventor
Robert J Altenbach
Andrew Bogdan
Sylvain Couty
Nicolas Desroy
Gregory A Gfesser
Philip R Kym
Bo Liu
Thi Thu Trang Mai
Karine Fabienne Malagu
Merayo Nuria Merayo
Olivier Laurent Picolet
Xenia B Searle
Der Plas Steven Emiel Van
Xueqing Wang
Ming C Yeung
Christopher Gaëtan Housseman
Mathieu Rafaël Pizzonero
Original Assignee
Abbvie Overseas Sarl
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Overseas Sarl, Galapagos Nv filed Critical Abbvie Overseas Sarl
Application granted granted Critical
Publication of DK3681864T3 publication Critical patent/DK3681864T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK18779798.0T 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSE TRANSMEMBRANE CONDUCTIVE POWER REGULATOR PROTEIN AND METHODS OF USE DK3681864T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558430P 2017-09-14 2017-09-14
US201762608846P 2017-12-21 2017-12-21
PCT/IB2018/057020 WO2019053634A1 (en) 2017-09-14 2018-09-13 Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Publications (1)

Publication Number Publication Date
DK3681864T3 true DK3681864T3 (en) 2021-01-25

Family

ID=63713961

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18779798.0T DK3681864T3 (en) 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSE TRANSMEMBRANE CONDUCTIVE POWER REGULATOR PROTEIN AND METHODS OF USE
DK20183405.8T DK3736267T3 (en) 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSET TRANSMEBRANE CONDUCTOR POWER REGULATOR PROTEIN AND APPLICATION PROCEDURES
DK20183402.5T DK3736270T3 (en) 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSET TRANSMEBRANE CONDUCTOR POWER REGULATOR PROTEIN AND APPLICATION PROCEDURES

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK20183405.8T DK3736267T3 (en) 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSET TRANSMEBRANE CONDUCTOR POWER REGULATOR PROTEIN AND APPLICATION PROCEDURES
DK20183402.5T DK3736270T3 (en) 2017-09-14 2018-09-13 MODULATORS OF THE CYSTIC FIBROSET TRANSMEBRANE CONDUCTOR POWER REGULATOR PROTEIN AND APPLICATION PROCEDURES

Country Status (33)

Country Link
US (6) US10988454B2 (en)
EP (4) EP3865474A1 (en)
JP (4) JP7064072B2 (en)
KR (1) KR20200086661A (en)
CN (1) CN111954664A (en)
AU (1) AU2018332512A1 (en)
BR (1) BR112020005102A2 (en)
CA (1) CA3074945A1 (en)
CL (1) CL2020000664A1 (en)
CO (1) CO2020004249A2 (en)
CR (1) CR20200157A (en)
CY (3) CY1123761T1 (en)
DK (3) DK3681864T3 (en)
EC (1) ECSP20021913A (en)
ES (3) ES2856751T3 (en)
HR (3) HRP20210099T1 (en)
HU (3) HUE052873T2 (en)
IL (1) IL273163A (en)
LT (3) LT3681864T (en)
MA (1) MA50240B1 (en)
MD (3) MD3736270T2 (en)
MX (1) MX2020002806A (en)
PE (1) PE20210140A1 (en)
PH (1) PH12020500509A1 (en)
PL (3) PL3736270T3 (en)
PT (3) PT3736270T (en)
RS (3) RS62185B1 (en)
RU (1) RU2020113350A (en)
SG (1) SG11202002101RA (en)
SI (3) SI3736270T1 (en)
UA (1) UA125541C2 (en)
WO (1) WO2019053634A1 (en)
ZA (1) ZA202002363B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3203840T3 (en) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2018064632A1 (en) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018107100A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112019025801A2 (en) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated treatment methods for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
SG11202003428VA (en) 2017-10-18 2020-05-28 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
PT3752510T (en) 2018-02-15 2023-03-15 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN113226464A (en) * 2018-12-18 2021-08-06 诺华股份有限公司 N- (pyridin-2-ylsulfonyl) cyclopropanecarboxamide derivatives and their use in the treatment of CFTR mediated diseases
TW202120517A (en) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 Process of making cftr modulators
TW202115092A (en) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 Modulators of cystic fibrosis transmembrane conductance regulator
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
US20220211692A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150173A1 (en) * 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602426A (en) * 1945-10-24 1948-05-26 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
KR20030036917A (en) * 2000-10-10 2003-05-09 스미스클라인 비참 코포레이션 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-γBINDING AGENTS
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
LT2489659T (en) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MX2009004702A (en) 2006-11-03 2009-06-19 Vertex Pharma Azaindole derivatives as cftr modulators.
AU2008256717B2 (en) 2007-05-25 2013-11-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BRPI0816116A2 (en) * 2007-08-29 2015-03-03 Schering Corp 2,3-SUBSTITUTED INDOL DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS.
JP5249344B2 (en) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション Indole derivatives substituted at the 3-position of the heterocyclic ring and use thereof
JP5455922B2 (en) 2007-12-10 2014-03-26 ノバルティス アーゲー Organic compounds
JP5637859B2 (en) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Modulator of cystic fibrosis membrane conductance regulator
EP2279029A2 (en) 2008-03-25 2011-02-02 The Regents of the University of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
DK2358680T3 (en) 2008-10-23 2013-06-24 Vertex Pharma Solid forms of n- (4- (7-azabicyclo [2.2.1] heptan-7-yl) -2- (trifluoromethyl) phenyl) -3-oxo-5- (trifluoromethyl) -1,4-dihydroquinoline-3 carboxamide
EP2940016A1 (en) 2008-11-06 2015-11-04 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN102458122A (en) * 2009-04-20 2012-05-16 人类健康研究所 Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
MX368263B (en) 2013-05-07 2019-09-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
CN103484818A (en) 2013-09-25 2014-01-01 京东方科技集团股份有限公司 Vapor deposition method, vapor deposition device and light-emitting device
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
KR102132215B1 (en) 2014-04-03 2020-07-09 삼성전자주식회사 Method for forming a magnatic tunnel junction structure and method for manufacturing a MRAM using the same
PL3203840T3 (en) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
SI3212189T1 (en) 2014-10-31 2020-11-30 Abbvie Overseas S.A R.L. Substituted chromanes and method of use
AU2015339196A1 (en) 2014-10-31 2017-05-11 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
CA2988046A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
ES2829636T3 (en) 2015-10-09 2021-06-01 Abbvie Overseas Sarl N-sulfonylated pyrazolo [3,4-b] pyridine-6-carboxamides and method of use
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Also Published As

Publication number Publication date
EP3736270B1 (en) 2021-05-05
KR20200086661A (en) 2020-07-17
PL3681864T4 (en) 2021-05-17
US20200277275A1 (en) 2020-09-03
CY1124615T1 (en) 2022-07-22
LT3736270T (en) 2021-08-25
SI3736270T1 (en) 2021-09-30
MD3736270T2 (en) 2021-11-30
LT3736267T (en) 2021-08-25
LT3681864T (en) 2021-02-25
WO2019053634A1 (en) 2019-03-21
SG11202002101RA (en) 2020-04-29
RU2020113350A3 (en) 2022-04-14
EP3736270A1 (en) 2020-11-11
CY1124401T1 (en) 2022-07-22
PL3681864T3 (en) 2021-05-17
JP7064074B2 (en) 2022-05-10
HRP20211200T1 (en) 2021-10-29
RS62185B1 (en) 2021-08-31
JP2022000460A (en) 2022-01-04
PL3736267T3 (en) 2021-11-15
JP2020534360A (en) 2020-11-26
US20200277276A1 (en) 2020-09-03
US20200277273A1 (en) 2020-09-03
PE20210140A1 (en) 2021-01-21
US20190077784A1 (en) 2019-03-14
DK3736267T3 (en) 2021-08-09
CA3074945A1 (en) 2019-03-21
JP7064072B2 (en) 2022-05-10
JP2022062093A (en) 2022-04-19
PT3681864T (en) 2021-02-25
CN111954664A (en) 2020-11-17
HRP20211198T1 (en) 2021-10-29
HUE055050T2 (en) 2021-10-28
RS62190B1 (en) 2021-08-31
ECSP20021913A (en) 2020-05-29
HRP20210099T1 (en) 2021-03-05
BR112020005102A2 (en) 2020-09-24
SI3681864T1 (en) 2021-08-31
CY1123761T1 (en) 2022-05-27
ES2856751T3 (en) 2021-09-28
UA125541C2 (en) 2022-04-13
PH12020500509A1 (en) 2021-05-31
PT3736267T (en) 2021-08-10
MA50240B1 (en) 2021-03-31
US10844042B2 (en) 2020-11-24
ES2887449T3 (en) 2021-12-22
EP3865474A1 (en) 2021-08-18
AU2018332512A1 (en) 2020-04-23
US10844041B2 (en) 2020-11-24
PL3736270T3 (en) 2021-11-15
US10829473B2 (en) 2020-11-10
US10981890B2 (en) 2021-04-20
DK3736270T3 (en) 2021-08-09
US10988454B2 (en) 2021-04-27
EP3736267A1 (en) 2020-11-11
EP3681864B1 (en) 2020-10-28
SI3736267T1 (en) 2021-09-30
IL273163A (en) 2020-04-30
HUE052873T2 (en) 2021-05-28
ZA202002363B (en) 2021-06-30
EP3681864A1 (en) 2020-07-22
CR20200157A (en) 2021-02-16
HUE055241T2 (en) 2021-11-29
RS61899B1 (en) 2021-06-30
RU2020113350A (en) 2021-10-15
PT3736270T (en) 2021-08-10
US20200277274A1 (en) 2020-09-03
MA50240A (en) 2020-07-22
MD3736267T2 (en) 2021-11-30
JP2022000461A (en) 2022-01-04
MX2020002806A (en) 2020-10-12
US20210238159A1 (en) 2021-08-05
CO2020004249A2 (en) 2020-08-31
CL2020000664A1 (en) 2020-11-06
EP3736267B1 (en) 2021-05-05
ES2881881T3 (en) 2021-11-30
JP7064073B2 (en) 2022-05-10
MD3681864T2 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
DK3681864T3 (en) MODULATORS OF THE CYSTIC FIBROSE TRANSMEMBRANE CONDUCTIVE POWER REGULATOR PROTEIN AND METHODS OF USE
DK3551622T3 (en) MODULATOR OF TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSE, PHARMACEUTICAL COMPOSITIONS, TREATMENT PROCEDURES AND METHOD OF MANUFACTURE OF THE MODULATOR
DK3910714T3 (en) ELECTROLYTE AND ELECTROCHEMICAL DEVICE
DK3203840T3 (en) MODULATORS OF CYSTIC FIBROSE TRANSMEMBRANE CONDUCTANCE REGULATOR
DK3500593T3 (en) UNKNOWN T-CELL RECEPTORS AND IMMUNTERY THERAPY USING IT
DK3454871T3 (en) MANIPULATED NATURAL KILLER CELLS AND APPLICATIONS THEREOF
DK3529257T3 (en) OXYSTEROLS AND METHODS OF USING THEREOF
DK3668512T3 (en) PYRUVACKINASE MODULATORS AND USES THEREOF
DK3484865T3 (en) SOMATOSTATIN MODULATORS AND USES THEREOF
DK3417058T3 (en) Sortase-modified molecules and their uses
DK3568914T3 (en) Power supply system and procedure
DK3551786T3 (en) ELECTROPOLATION PROCEDURE AND ELECTROLYTE THEREOF
DK3490988T3 (en) New connection and approach
DK3478711T3 (en) HERV-E-REACTIVE T CELL RECEPTORS AND METHODS OF USING THEM
DK3282584T3 (en) Power distribution system and procedure
DK3304240T3 (en) POWER CONFERENCES AND RELATED POWER
DK3639341T3 (en) ELECTRICAL POWER SYSTEMS AND METHODS OF CONTROLLING THE SAME
DK3430087T3 (en) SKIN ADHESIVE SILICONE GEL
TWI838492B (en) Certification devices and membranes
ES1207937Y (en) PORTABLE ELECTRIC GENERATOR
UA35241S (en) ELECTRIC GUITAR
UA35218S (en) ELECTRIC GUITAR
IT201700102644A1 (en) APPLICATOR AND EQUIPMENT FOR ELECTROPORATION
DK3410567T3 (en) Magnetic field generating device and current receiving device
AU2016902413A0 (en) Proteinaceous molecules and methods of use